National Institutes of Health Clinical Center

CLS Americas Announces the National Institutes of Health Clinical Center Placed its 1st Order of the TRANBERG™ Thermal Therapy System for its Research Study - MRI/Ultrasound Fusion-Guided FLA of Prostate Tissue and Prostate Cancer

Retrieved on: 
Thursday, June 1, 2023
Male, National Institutes of Health Clinical Center, NIHCC, CLS, Temperature, Bangladesh Technical Education Board, FLA, Patient, Urology, Diagnosis, Erectile dysfunction, NIH, Urinary incontinence, Prostate cancer, Medical imaging

The order falls under the previously announced research collaboration agreement between NIHCC and its parent company, Clinical Laserthermia Systems AB, based in Sweden.

Key Points: 
  • The order falls under the previously announced research collaboration agreement between NIHCC and its parent company, Clinical Laserthermia Systems AB, based in Sweden.
  • In the US, over one million prostate biopsies are performed every year leading to a diagnosis of prostate cancer for almost 250,000 men.
  • “CLS is pleased to begin this collaboration with the NIH to evaluate our TRANBERG laser for image-guided, focal therapies to treat prostate cancer,” said Michael Magnani, President of CLS Americas.
  • A TRANBE RG FLA Animation Video of the system and procedure is available to watch.

CLS Americas Announces Research Collaboration with the National Institutes of Health Clinical Center to Study MRI/Ultrasound Fusion-Guided FLA of Prostate Tissue and Prostate Cancer

Retrieved on: 
Thursday, April 13, 2023
Male, National Institutes of Health Clinical Center, NIHCC, Quality of life, CLS, Temperature, Bangladesh Technical Education Board, FLA, Patient, Urology, Diagnosis, Erectile dysfunction, NIH, Urinary incontinence, Prostate cancer, Medical imaging

Under the agreement, NIHCC will access the clinical utility of the CLS’s TRANBERG® Thermal Therapy System towards MRI/Ultrasound fusion-guided focal laser ablation (FLA) of prostate tissue and prostate cancer in male patients.

Key Points: 
  • Under the agreement, NIHCC will access the clinical utility of the CLS’s TRANBERG® Thermal Therapy System towards MRI/Ultrasound fusion-guided focal laser ablation (FLA) of prostate tissue and prostate cancer in male patients.
  • In the US, over one million prostate biopsies are performed every year leading to a diagnosis of prostate cancer for almost 250,000 men.
  • “CLS is honored to initiate this collaboration with the NIH to evaluate our TRANBERG laser for image-guided, focal therapies to treat prostate cancer,” said Michael Magnani, President of CLS Americas.
  • It includes a desk-top mobile laser unit, innovative non-cooled laser applicators, tissue temperature probes, and procedure-specific accessories.

$1.67M NIH Grant Brings Scene Health’s Medication Support to Florida Pediatric Heart Transplant Centers

Retrieved on: 
Thursday, April 6, 2023
Software, Mobile, Wireless, Pharmaceutical, Consumer, Apps, Applications, Technology, Health Technology, Teens, Surgery, Children, Cardiology, Audio, Video, Health, Asthma, University, Diabetes, Hospital, Florida State University, SBIR, Cholesterol, National Heart, Lung, and Blood Institute, Opioid use disorder, Initiative, Medicine, DRS, Research, Lung, Bangladesh Technical Education Board, Hepatitis C, National Institutes of Health Clinical Center, CDC, Science, Hypertension, Social work, NHLBI, Pharmacist, DOT, Patient, Physician, Risk, Nursing, Adherence (medicine), Tuberculosis, Small Business Innovation Research, Adolescence, Sickle cell disease, MSW, Florida State University College of Social Work, Death, NIH, Directly observed treatment, short-course, Pharmaceutical industry, Dentistry, Medical device

This grant will allow the investigators to perform a randomized control trial to assess the impact of video DOT on a larger scale and across multiple pediatric heart transplant centers.

Key Points: 
  • This grant will allow the investigators to perform a randomized control trial to assess the impact of video DOT on a larger scale and across multiple pediatric heart transplant centers.
  • The initiative taps into a statewide network of health researchers, clinicians and pediatric heart transplant centers.
  • Medication adherence is critical for pediatric heart transplant patients, especially adolescent patients who struggle to take their medications consistently, often due to social factors.
  • "This NIH grant will allow Scene Health to expand our efforts to support medication adherence in one of the highest-risk patient populations,” notes Sebastian Seiguer, co-founder and CEO of Scene Health.

Arkstone's Treatment Recommendations Now Include Realtime National Institute of Health (NIH) Data

Retrieved on: 
Thursday, March 16, 2023
Gene, Entrepreneurship, Risk, Microbiology, Prevalence, NIH, Patient, Infection, Incidence, BOCA, National Institutes of Health Clinical Center, Literature, PCR, Disulfiram-like drug, Pharmaceutical industry, Antibiotics, Vaccine

Antibiotic resistance is a growing concern in the healthcare industry, with an estimated 2.8 million antibiotic-resistant infections occurring in the United States each year.

Key Points: 
  • Antibiotic resistance is a growing concern in the healthcare industry, with an estimated 2.8 million antibiotic-resistant infections occurring in the United States each year.
  • When indicated, the report provides a suggested optimal treatment regimen that safely and efficiently treats the patient and properly targets the detected infection.
  • The NIH has been collecting lab result isolate data for decades, compiling information about the prevalence of antimicrobial resistance genes in specific organisms.
  • This data is collected from clinical and public health laboratories across the country and provides a comprehensive insight into which organisms are likely to express which genes.

Muscular Dystrophy Association Announces Recipient of 2023 MDA Legacy Award for Achievement in Clinical Research is Merit Cudkowicz, MD, MSC, Renowned Neurologist and Clinical Researcher in ALS

Retrieved on: 
Monday, March 6, 2023
MD, Healey, Houston Methodist Hospital, Muscular Dystrophy Association, Health, MSC, Research, Bangladesh Technical Education Board, NIH, Stroke, MDA, Neuromuscular disease, DSM-IV codes, Mentorship, Patient, Massachusetts General Hospital, Hope, Doctor of Philosophy, Muscular dystrophy, Episcopal conference, Conference, Hospital, National Institute of Neurological Disorders and Stroke, Cellular, National Institutes of Health Clinical Center, Mass, Pharmaceutical industry, ALS

New York, NY, March 06, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Merit Cudkowicz, MD, MSC , a renowned neurologist and clinical researcher in ALS (amyotrophic lateral sclerosis, aka Lou Gehrig’s disease, or motor neuron disease) from Massachusetts General Hospital, will receive the 2023 MDA Legacy Award for Achievement in Clinical Research.

Key Points: 
  • New York, NY, March 06, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Merit Cudkowicz, MD, MSC , a renowned neurologist and clinical researcher in ALS (amyotrophic lateral sclerosis, aka Lou Gehrig’s disease, or motor neuron disease) from Massachusetts General Hospital, will receive the 2023 MDA Legacy Award for Achievement in Clinical Research.
  • The MDA Legacy Award for Achievement in Clinical Research is an annual recognition for outstanding accomplishments in neuromuscular disease research.
  • “We at the Muscular Dystrophy Association are extremely proud to honor Dr. Cudkowicz with the 2023 MDA Legacy Award for Achievement in Clinical Research.
  • Dr. Appel is the MDA Care Center Director at Houston Methodist Neurological Institute's MDA ALS Research and Clinical Center in Houston.

Shuttle Pharmaceuticals Expands Laboratory Space to Advance Drug Development Pipeline and Diagnostic Capabilities

Retrieved on: 
Thursday, February 23, 2023
Cancer, RT, Immune system, Brain, Investigational New Drug, TCG, National Cancer Institute, Research, National Institutes of Health Clinical Center, FDA, Patient, Trial of the century, Acceleration, Shuttle, Bangladesh Technical Education Board, Glioblastoma, Pharmaceutical industry

The new laboratory space, located in Gaithersburg, Maryland, is located within the Maryland Biotech Corridor.

Key Points: 
  • The new laboratory space, located in Gaithersburg, Maryland, is located within the Maryland Biotech Corridor.
  • Shuttle Pharma's platform of sensitizers offers a pipeline of product candidates designed to address the urgent clinical need for new radiation sensitizer agents.
  • The Company's pipeline includes Ropidoxuridine, its lead clinical sensitizer drug candidate, to sensitize rapidly growing cancer cells and selective histone deacetylase inhibitors to sensitize cancer cells and stimulate the immune system.
  • "The expansion of our laboratory space is critical to the advancement of our drug development pipeline and acceleration of our broader diagnostic capabilities on predictive biomarkers," commented Shuttle Pharma's Chairman and CEO, Anatoly Dritschilo, M.D.

Immunization Stress-Related Response Mimics Vaccine-induced Anaphylaxis to COVID-19 Vaccines

Retrieved on: 
Friday, February 10, 2023
National Institutes of Health Clinical Center, Dizziness, Messenger, Journal, Hypoesthesia, Bangladesh Technical Education Board, Vaccination, William Frankland (allergist), Safety, AAAAI, Patient, Asthma, American Academy of Allergy, Asthma, and Immunology, Clinical trial, The Journal of Allergy and Clinical Immunology, Research, Infection, Dysphagia, ISRR, Laboratory, Doctor of Philosophy, Anaphylaxis, NIAID, American Academy, COVID-19, Vaccine, Pharmaceutical industry, Pfizer, Immunology, Allergy, MD

MILWAUKEE, Feb. 10, 2023 /PRNewswire-PRWeb/ -- COVID-19 mRNA Vaccine-induced Immunization Stress-Related Response (ISRR) mimics many symptoms of anaphylaxis, which is likely one of the explanations for higher reports of allergic reactions during COVID-19 vaccination. These findings are being presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) by Muhammad B. Khalid, MD, who led the research with Dr. Pamela A. Frischmeyer-Guerrerio, MD, PhD. Dr. Khalid is a clinical fellow in the Laboratory of Allergic Diseases of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Dr. Guerrerio is the principal investigator for this research and chief of the NIAID Laboratory of Allergic Diseases.

Key Points: 
  • MILWAUKEE, Feb. 10, 2023 /PRNewswire-PRWeb/ -- COVID-19 mRNA Vaccine-induced Immunization Stress-Related Response (ISRR) mimics many symptoms of anaphylaxis, which is likely one of the explanations for higher reports of allergic reactions during COVID-19 vaccination.
  • COVID-19 mRNA vaccine anaphylaxis has been reported at higher rates than conventional vaccine anaphylactic reactions.
  • While anaphylaxis can rarely occur following COVID-19 vaccination, ISRR is a highly under-recognized mimic, Dr. Khalid and colleagues report.
  • Due to the similarity of ISRR symptoms to those of anaphylaxis, the rate of true anaphylaxis following COVID-19 vaccination is likely lower than estimated, based on the study findings.

Actinium Signs Cooperative Research and Development Agreement with National Cancer Institute to Further Enhance Clinical and Non-clinical Development of Actimab-A for the Treatment of Acute Myeloid Leukemia and Other Hematologic Malignancies

Retrieved on: 
Monday, February 6, 2023
Actinium, Bone marrow, AML, NCI, TP53, CRADA, Collaboration, Immunotherapy, Experiment, National Cancer Institute, Development, Bangladesh Technical Education Board, NIH, CTEP, NYSE, Radiation, Patient, Alliance for Clinical Trials in Oncology, Eastern Cooperative Oncology Group, Clinical trial, Lois, SWOG, Survival, Letter, American College, Acute myeloid leukemia, Cooperative research and development agreement, National Institutes of Health Clinical Center, Pharmaceutical industry

NEW YORK, Feb. 6, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes for Health (NIH), to develop Actimab-A for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. Under the terms of the CRADA, the NCI will serve as the regulatory sponsor for any clinical trials mutually approved by both parties to study Actimab-A while Actinium will be responsible for supplying and distributing Actimab-A to participating clinical sites and providing additional support as needed. The CRADA will provide broad support for the development of Actimab-A alone or in combination with chemotherapy, immunotherapy, targeted agents and other novel combinations, in line with Actinium's strategy of leveraging Actimab-A's targeted radiotherapy mechanism to elicit synergistic effects.

Key Points: 
  • The CRADA studies will be overseen by NCI in collaboration with Actinium's clinical development team.
  • Actimab-A studies may also be conducted through NCI's MyeloMATCH program.
  • Dr. Avinash Desai, Chief Medical Officer of Actinium Pharmaceuticals, commented, "NCI's broad support under the CRADA is a strong encouragement for us to together explore Actimab-A's potential for the treatment of AML and other hematologic malignancies.
  • We look forward to working collaboratively with the NCI and all investigators through this CRADA to complete multiple clinical trials to further realize Actimab-A's therapeutic potential."

3DR Labs welcomes board-certified diagnostic radiologist to Cardiac Center of Excellence

Retrieved on: 
Tuesday, January 10, 2023
Associate, University, National Institutes of Health Clinical Center, Software testing certification board, Case Western Reserve University, Division, University of Pittsburgh Medical Center, American Board of Commissioners for Foreign Missions, Society, The Massachusetts, MD, Magnetic resonance, Massachusetts General Hospital, Hospital, CT, Society of Cardiovascular Computed Tomography, American Board of Radiology, Chief Medical Advisor to the President, MGH, Radiology, HMS, Pennsylvania Hospital, Weatherhead School of Management, MRI, Harvard Medical School, OH, MBA, Labs, Medical imaging, Health

Louisville, KY, Jan. 10, 2023 (GLOBE NEWSWIRE) -- 3DR Imaging, LLC is pleased to announce the appointment of Brian Ghoshhajra, MD, MBA, to its Cardiac Center of Excellence as its Medical Advisor.

Key Points: 
  • Louisville, KY, Jan. 10, 2023 (GLOBE NEWSWIRE) -- 3DR Imaging, LLC is pleased to announce the appointment of Brian Ghoshhajra, MD, MBA, to its Cardiac Center of Excellence as its Medical Advisor.
  • Dr. Ghoshhajra is a board-certified Diagnostic Radiologist with advanced training in Cardiovascular Computed Tomography (CT) and Cardiovascular Magnetic Resonance Imaging (MRI).
  • As the Medical Advisor to 3DR’s Cardiac Center of Excellence, Dr. Ghoshhajra’s vast experience in advanced cardiovascular imaging (including CT and MRI) will support 3DR’s ability to deliver the highest quality post processing services in the rapidly expanding advanced cardiac imaging market.
  • “We are incredibly excited to have Dr. Ghoshhajra’s leadership, expertise and capability in our new Cardiac Center of Excellence”, said Dave Levine, Vice President and General Manager, 3DR Labs.

Over 20 Million Suffer From Peripheral Neuropathy, St. Pete Medical Group Aims to Help

Retrieved on: 
Wednesday, December 14, 2022
Weight loss, Quality of life, Hypoesthesia, Peripheral neuropathy, Extremities, Erectile dysfunction, Paresthesia, Boston Medical Group, Pain, Telehealth, National Institutes of Health Clinical Center, Growth, Patient, Health insurance, Pharmaceutical industry, Medicine, Tampa Bay

ST. PETERSBURG, Fla., Dec. 14, 2022 (GLOBE NEWSWIRE) -- St. Pete Medical Group and Clearwater Medical Group were featured on 10 Tampa Bay's Great Day Live .

Key Points: 
  • ST. PETERSBURG, Fla., Dec. 14, 2022 (GLOBE NEWSWIRE) -- St. Pete Medical Group and Clearwater Medical Group were featured on 10 Tampa Bay's Great Day Live .
  • "We're passionate about helping our patients find relief from their symptoms and improve their quality of life," said Spinoso, founder of St. Pete Medical Group.
  • For more information about St. Pete Medical Group and Clearwater Medical Group, or to schedule an appointment, please visit their website at www.stpetemedicalgroup.com or call (727)-354-8744.
  • ABOUT ST PETE MEDICAL GROUP: St. Pete Medical Group's mission is to create a comfortable experience for you.